CoChat

Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease

Cassano, Tommaso, Magini, Alessandro, Giovagnoli, Stefano, Polchi, Alice, Calcagnini, Silvio, Pace, Lorenzo, Lavecchia, Michele Angelo, Scuderi, Caterina, Bronzuoli, Maria Rosanna, Ruggeri, Loredana, Gentileschi, Maria Pia, Romano, Adele, Gaetani, Silvana, De Marco, Federico, Emiliani, Carla, Dolcetta, Diego · 2019 · Experimental Neurology
Cited by 66

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

&NA; The discovery that mammalian target of rapamycin (mTOR) inhibition increases lifespan in mice and restores/delays many aging phenotypes has led to the identification of a novel potential therapeutic target for the treatment of Alzheimer's disease (AD). Among mTOR inhibitors, everolimus, which has been developed to improve the pharmacokinetic characteristics of rapamycin, has been extensively profiled in preclinical and clinical studies as anticancer and immunosuppressive agent, but no information is available about its potential effects on neurodegenerative disorders. Using a reliable mouse model of AD (3 × Tg‐AD mice), we explored whether short‐term treatment with everolimus injected directly into the brain by osmotic pumps was able to modify AD‐like pathology with low impact on peripheral organs. We first established in non‐transgenic mice the stability of everolimus at 37 °C in comparison with rapamycin and, then, evaluated its pharmacokinetics and pharmacodynamics profiles through either a single peripheral (i.p.) or central (i.c.v.) route of administration. Finally, 6‐month‐old (symptomatic phase) 3 × Tg‐AD mice were treated with continuous infusion of either vehicle or everolimus (0.167 &mgr;g/&mgr;l/day, i.c.v.) using the osmotic pumps. Four weeks after the beginning of infusion, we tested our hypothesis following an integrated approach, including behavioral (tests for cognitive and depressive‐like alterations), biochemical and immunohistochemical analyses. Everolimus (i) showed higher stability than rapamycin at 37 °C, (ii) poorly crossed the blood‐brain barrier after i.p. injection, (iii) was slowly metabolized in the brain due to a longer t1/2 in the brain compared to blood, and (iv) was more effective in the CNS when administered centrally compared to a peripheral route. Moreover, the everolimus‐induced mTOR inhibition reduced human APP/A&bgr; and human tau levels and improved cognitive function and depressive‐like phenotype in the 3 × Tg‐AD mice. The intrathecal infusion of everolimus may be effective to treat early stages of AD‐pathology through a short and cyclic administration regimen, with short‐term outcomes and a low impact on peripheral organs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.expneurol.2018.09.011

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 66

Metadata

Authors
Cassano, T., Magini, A., Giovagnoli, S., Polchi, A., Calcagnini, S., Pace, L., Lavecchia, M. A., Scuderi, C., Bronzuoli, M. R., Ruggeri, L., Gentileschi, M. P., Romano, A., Gaetani, S., De Marco, F., Emiliani, C., & Dolcetta, D.
Venue
Experimental Neurology
Publisher
Elsevier BV
Published
2019-01
Volume
311
Pages
88-105
ISSN
0014-4886 (ISSN-L)
OpenAlex
W2889700070
Cited by
66
References
14
FWCI
3.12
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.expneurol.2018.09.011
The paper
Cassano, T., Magini, A., Giovagnoli, S., Polchi, A., Calcagnini, S., Pace, L., Lavecchia, M. A., Scuderi, C., Bronzuoli, M. R., Ruggeri, L., Gentileschi, M. P., Romano, A., Gaetani, S., De Marco, F., Emiliani, C., & Dolcetta, D. (2019). Early intrathecal infusion of everolimus restores cognitive function and mood in a murine model of Alzheimer's disease. Experimental Neurology. https://doi.org/10.1016/j.expneurol.2018.09.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.